Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring Hyperhidrosis Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy MED201.014

    Treatment of Hyperhidrosis

    Customize your policy alerts

    Sign up for healthspring Policy MED201.014 alerts

    Get alerted when Policy MED201.014 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage determinations for treatments of primary focal and severe secondary gustatory hyperhidrosis, including medically necessary, experimental or unproven, and not medically necessary treatments.

    Policy Summary
    PayerHealthSpring
    PolicyTreatment of Hyperhidrosis
    Policy CodePolicy MED201.014
    Change TypeNew medical document
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionTry conservative therapy before invasive treatment for primary hyperhidrosis.
    SourceLink
    POLICY UPDATE CHANGES

    New medical document establishes that treatment of hyperhidrosis may be considered medically necessary when the coverage criteria are met.

    4Primary focal regions addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+
    Minimum age for onabotulinumtoxinA
    1-4Disease Severity Scale range
    <16STS onset criterion

    Medical Necessity and Coverage Criteria

    Primary focal hyperhidrosis

    Treatment of primary focal hyperhidrosis may be considered medically necessary when a qualifying condition is present and the requested treatment is listed as medically necessary for the affected focal region.

    Primary focal hyperhidrosis medical necessity

    • Qualifying condition

      • Acrocyanosis of the hands.
      • Recurrent maceration and infection: History of recurrent skin maceration with bacterial or fungal infections.
      • Recurrent secondary infection: History of recurrent secondary infections.
      • Persistent eczematous dermatitis: History of persistent eczematous dermatitis despite medical treatment with topical dermatologic or systemic anticholinergic agents.
    • Medically necessary treatment by focal region

      • Axillary: OnabotulinumtoxinA for severe primary axillary hyperhidrosis inadequately managed with topical agents in patients 18 years and older; or endoscopic transthoracic sympathectomy or surgical excision of axillary sweat glands if conservative treatment has failed.18 years and older for onabotulinumtoxinA

        OnabotulinumtoxinA is the only botulinum toxin product identified as FDA-approved for this indication.

      • Palmar: Endoscopic transthoracic sympathectomy if conservative treatment has failed.
      • Craniofacial: Endoscopic transthoracic sympathectomy if conservative treatment has failed.
      • Plantar: No treatment is listed as medically necessary for plantar hyperhidrosis in Table 1.

    Secondary gustatory hyperhidrosis

    Treatment of severe secondary gustatory hyperhidrosis may be considered medically necessary when conservative treatment has failed.

    Severe secondary gustatory hyperhidrosis

    • Medically necessary treatment

      • Surgical treatment: Surgical options, such as tympanic neurectomy.

    Endoscopic thoracic sympathectomy selection criteria

    STS-recommended patient criteria for endoscopic thoracic sympathectomy in severe primary hyperhidrosis.

    All selection criteria

    • Severe refractory disease: Severe symptoms that cannot be managed with other therapies.
    • Age and onset: Onset of hyperhidrosis before age 16 and age less than 25 years at the time of surgery.Onset before 16 years; age <25 years at surgery
    • Physiologic and clinical criteria: Body mass index less than 28 kg/m2, no sweating during sleep, no significant comorbidities, and resting heart rate less than 55 beats per minute.BMI <28 kg/m2; resting heart rate <55 beats per minute

    NICE upper-limb sympathectomy criteria

    NICE guidance for endoscopic thoracic sympathectomy.

    Severe refractory upper-limb hyperhidrosis: Consider endoscopic thoracic sympathectomy only for patients with severe and debilitating primary hyperhidrosis of the upper limb that is refractory to other treatments.

    The restriction reflects the risk of side effects.

    Axillary treatment sequencing

    For primary focal axillary hyperhidrosis, conservative treatment should precede invasive treatment.

    Conservative therapy first: Try more conservative therapy before resorting to invasive treatment for primary focal axillary hyperhidrosis.

    The International Hyperhidrosis Society algorithm mentions subdermal laser therapy only after numerous other treatments have failed.

    For primary focal hyperhidrosis, the following treatments are considered experimental, investigational, and/or unproven: axillary liposuction, iontophoresis, microwave treatment, and radiofrequency ablation; palmar rimabotulinumtoxinB, iontophoresis, microwave treatment, radiofrequency ablation, and subdermal laser treatment; plantar onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB, iontophoresis, lumbar sympathectomy, microwave treatment, and radiofrequency ablation; and craniofacial subdermal laser treatment, botulinum toxin products, iontophoresis, microwave treatment, and radiofrequency ablation. Treatment selection is limited to the medically necessary options identified for the affected focal region, and invasive treatment generally follows failure of conservative therapy.

    For severe secondary gustatory hyperhidrosis, botulinum toxin, iontophoresis, and subdermal laser treatment are considered experimental, investigational, and/or unproven. Surgical options, such as tympanic neurectomy, may be considered medically necessary when conservative treatment has failed.

    The miraDry system was FDA-cleared through the 510(k) process for treating primary axillary hyperhidrosis. It is not currently approved for palmar or plantar hyperhidrosis; therefore, the device’s regulatory clearance does not extend to those treatment sites.

    Treatment of hyperhidrosis is not medically necessary when there is no functional impairment and no medical condition included in the policy to support treatment. Documentation should establish the affected region, the clinical impact of the condition, and any qualifying medical condition or complication.

    Coding and Clinical Thresholds

    Home iontophoresis deviceHCPCS
    E1399May be used for home iontophoresis devices; there are no specific HCPCS codes for these DME devices.
    CPT CodesCPT
    11450
    11451
    32664
    64650
    64653
    64802
    64804
    64809
    64818
    64820
    1–10 of 14
    1/2
    HCPCS CodesHCPCS
    E1399
    J0585
    J0586
    J0587
    J0588
    J3490
    Hyperhidrosis Disease Severity Scale
    Scale range1 to 4
    Score 1Sweating is never noticeable and never interferes with daily activities.
    Score 4Sweating is intolerable and always interferes with daily activities.
    OnabotulinumtoxinA age threshold
    Minimum age18 years and older
    ConditionSevere primary axillary hyperhidrosis inadequately managed with topical agents

    Documentation and Decision Guidance

    Step Therapy

    Conservative Treatment Before Invasive Therapy

    Document conservative treatment before invasive therapy. Record the step-therapy sequence, including topical or other conservative therapies attempted, response, duration, and reason for escalation; the International Hyperhidrosis Society recommends trying more conservative therapy before invasive treatment. Apply applicable NICE limitations when documenting endoscopic thoracic sympathectomy (ETS) or microwave ablation.

    Documentation Required

    Establish Diagnosis and Medical Necessity

    Establish the diagnosis and medical necessity by documenting whether the condition is primary focal or severe secondary gustatory hyperhidrosis, the affected region, severity, and functional impairment. For primary focal hyperhidrosis, identify a qualifying condition such as acrocyanosis, recurrent skin maceration or secondary infection, or persistent eczematous dermatitis despite appropriate treatment.

    • Document the affected region: axillary, palmar, plantar, or craniofacial.
    • For secondary gustatory hyperhidrosis, document the underlying qualifying condition and severity.

    Condition Overview

    Hyperhidrosis is excessive sweating beyond what is required to maintain normal body temperature in response to heat exposure or exercise. It may impair psychological and social functioning. Primary focal hyperhidrosis is idiopathic and commonly involves the hands, feet, or axillae, while secondary hyperhidrosis may be associated with medications or underlying disease. Secondary gustatory hyperhidrosis causes sweating of the scalp or face with food ingestion and may occur after injury to or surgery involving the parotid region.

    Policy Definitions

    Hyperhidrosis
    DefinitionExcessive sweating beyond a level required to maintain normal body temperature in response to heat exposure or exercise.
    ClassificationMay be classified as primary or secondary.
    Clinical impactThe consequences are primarily psychosocial.
    Primary focal hyperhidrosis
    DefinitionIdiopathic hyperhidrosis typically involving the hands, feet, or axillae.
    Palmar regionHands
    Other typical regionsFeet and axillae (underarms)
    Policy Summary
    PayerHealthSpring
    PolicyTreatment of Hyperhidrosis
    Policy CodePolicy MED201.014
    Change TypeNew medical document
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionTry conservative therapy before invasive treatment for primary hyperhidrosis.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Clinical ThresholdsDocumentation and Decision GuidanceCondition OverviewPolicy Definitions
    Treatment
    OnabotulinumtoxinA
    Age at onset
    Recommended onsetBefore 16 years
    Applies toEndoscopic thoracic sympathectomy selection
    Disease contextSevere symptoms that cannot be managed with other therapies
    Age at surgery
    Recommended age at surgeryLess than 25 years
    Applies toEndoscopic thoracic sympathectomy selection
    Recommendation sourceSociety of Thoracic Surgeons expert consensus statement
    Body mass index
    Recommended BMILess than 28 kg/m2
    Applies toEndoscopic thoracic sympathectomy selection
    Associated criteriaNo significant comorbidities and no sweating during sleep
    Resting heart rate
    Recommended resting heart rateLess than 55 beats per minute
    Applies toEndoscopic thoracic sympathectomy selection
    Disease contextSevere symptoms that cannot be managed with other therapies
    Documentation Required

    Document Conservative-Treatment Failure

    Document failure or inadequate response to conservative therapy before requesting a covered surgical or invasive treatment. Identify each therapy attempted, the treatment period, adherence, clinical response, and the reason it was discontinued or considered unsuccessful.

    • For axillary disease, document inadequate management with topical agents when requesting onabotulinumtoxinA.
    • For ETS, surgical excision, or tympanic neurectomy, document that conservative treatment has failed.
    Denial Risk

    No Functional Impairment or Qualifying Condition

    Treatment is not medically necessary when hyperhidrosis is submitted without documented functional impairment or without one of the qualifying medical conditions identified in the policy. Include the clinical impact and qualifying condition in the medical record and prior-authorization submission.

    • Absence of functional impairment is a denial condition.
    • A condition not included among the policy’s qualifying conditions is a denial condition.
    Denial Risk

    Experimental or Unproven Modality

    Check the requested modality and treatment region against the policy’s experimental, investigational, and/or unproven designations. Do not assume that a treatment considered medically necessary for one region or diagnosis is covered for another.

    • Examples listed as experimental, investigational, and/or unproven include axillary liposuction, iontophoresis, microwave treatment, radiofrequency ablation, and several botulinum toxin or laser treatments depending on region.
    • For severe secondary gustatory hyperhidrosis, botulinum toxin, iontophoresis, and subdermal laser treatment are listed as experimental, investigational, and/or unproven.
    Denial Risk

    Conservative Treatment Has Not Failed

    Surgical treatment may be denied when the record does not demonstrate that required conservative therapy was tried and failed. Before requesting ETS, surgical excision of axillary sweat glands, or tympanic neurectomy, submit documentation of the conservative-treatment sequence and inadequate response.

    • The policy requires conservative-treatment failure for axillary ETS or surgical excision.
    • The policy requires conservative-treatment failure for palmar or craniofacial ETS and for surgical options for severe secondary gustatory hyperhidrosis.
    Denial Risk

    ETS Requires Severe Refractory Disease

    Limit upper-limb ETS to patients with severe, debilitating primary hyperhidrosis that is refractory to other treatments. Document severity, functional burden, prior treatment failures, and the risk-benefit rationale before proceeding.

    • Apply the NICE limitation because of the risk of side effects.
    • Use the policy’s ETS requirement that conservative treatment has failed.
    Denial Risk

    Microwave Ablation Has Inadequate Evidence

    For severe primary axillary hyperhidrosis, advise that NICE found inadequate evidence in both quantity and quality to evaluate the safety and efficacy of transcutaneous microwave ablation. Treat the modality as subject to the policy’s experimental, investigational, and/or unproven limitation rather than as an established covered alternative.

    Denial Risk

    miraDry Site Limitation

    Confirm the treatment site before requesting or performing miraDry. The system was cleared for primary axillary hyperhidrosis but is not approved for palmar or plantar hyperhidrosis.

    • Use of miraDry for palmar or plantar hyperhidrosis presents a regulatory and coverage concern.
    Secondary gustatory hyperhidrosis
    DefinitionExcessive sweating on ingesting highly spiced foods.
    Typical distributionSymmetric sweating of the scalp or face, predominantly over the forehead, lips, and nose.
    Secondary facial formMay occur independently of the nature of the ingested food and frequently follows injury or surgery near the parotid gland.
    ETS
    AbbreviationETS
    Full termEndoscopic transthoracic sympathectomy
    Policy useListed as a treatment option for specified primary focal hyperhidrosis regions when conservative treatment has failed.
    miraDry system
    Device descriptionMicrowave device designed to heat tissue at the dermal-hypodermal interface, where sweat glands are located.
    Regulatory statusFDA-cleared in 2011 through the 510(k) process.
    Cleared indicationTreatment of primary axillary hyperhidrosis; it is not currently approved for palmar or plantar hyperhidrosis.
    NCT
    AbbreviationNCT
    MeaningNational clinical trial identifier
    Policy useUsed to identify ongoing and unpublished hyperhidrosis studies.